Literature DB >> 6932824

Pharmacokinetics of cefmetazole in normal subjects and in patients with impaired renal function.

M Ohkawa, M Orito, T Sugata, M Shimamura, M Sawaki, E Nakashita, K Kuroda, K Sasahara.   

Abstract

The pharmacokinetics of cefmetazole, a new cephamycin antibiotic, were examined after a 1-h intravenous drip infusion of 1 g to 5 healthy volunteers with normal renal function and 16 patients with impaired renal function. Peak serum concentrations were obtained at the end of the infusion in all subjects, regardless of their renal function. Approximately 70% of the infused dose was excreted in the urine within 6 h in healthy volunteers. The pharmacokinetic parameters of cefmetazole were derived by analyzing elimination data, with a one-compartment open model. The mean serum half-life of cefmetazole in healthy volunteers was 0.81 h. A significant correlation between the elimination rate constant and the creatinine clearance was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6932824      PMCID: PMC284011          DOI: 10.1128/AAC.18.3.386

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Comparative clinical pharmacology of intravenous cefoxitin and cephalothin.

Authors:  P F Sonneville; R R Kartodirdjo; H Skeggs; A E Till; C M Martin
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

2.  A new semisynthetic 7alpha-methoxycephalosporin, CS-1170: 7beta-((cyanomethyl)thio)acetamido)-7alpha-methoxy-3-((1-methyl-1H-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylic acid.

Authors:  H Nakao; H Yanagisawa; B Shimizu; M Kaneko; M Nagano
Journal:  J Antibiot (Tokyo)       Date:  1976-05       Impact factor: 2.649

Review 3.  Bioavailability and pharmacokinetics of cefoxitin sodium.

Authors:  J J Schrogie; R O Davies; K C Yeh; D Rogers; G I Holmes; H Skeggs; C M Martin
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

4.  Pharmacology of cefazolin in patients with normal and abnormal renal function.

Authors:  M E Levison; S P Levison; K Ries; D Kaye
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

5.  Pharmacokinetics of cefazolin compared with four other cephalosporins.

Authors:  W M Kirby; C Regamey
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

6.  Pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency.

Authors:  W A Craig; P G Welling; T C Jackson; C M Kunin
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

7.  Pharmacokinetics of cefoxitin sodium in normal subjects and in uraemic patients.

Authors:  J P Fillastre; A Leroy; M Godin; G Oksenhendler; G Humbert
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

8.  A guide to use of antibiotics in patients with renal disease. A table of recommended doses and factors governing serum levels.

Authors:  C M Kunin
Journal:  Ann Intern Med       Date:  1967-07       Impact factor: 25.391

9.  Cephamycins, a new family of beta-lactam antibiotics. IV. In vivo studies.

Authors:  A K Miller; E Celozzi; Y Kong; B A Pelak; H Kropp; E O Stapley; D Hendlin
Journal:  Antimicrob Agents Chemother       Date:  1972-10       Impact factor: 5.191

10.  Cefoxitin, a semisynthetic cephamycin antibiotic: susceptibility studies.

Authors:  H Wallick; D Hendlin
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

View more
  8 in total

1.  Pharmacokinetics and dose proportionality of cefmetazole in healthy young and elderly volunteers.

Authors:  M T Borin; G R Peters; T C Smith
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

2.  Disposition of cefmetazole in healthy volunteers and patients with impaired renal function.

Authors:  C E Halstenson; D R Guay; J A Opsahl; C A Hirata; L S Olanoff; E Novak; H Ko; K S Cathcart; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

3.  Pharmacokinetics of cefmetazole administered intramuscularly and intravenously to healthy adults.

Authors:  J Rodriguez-Barbero; E L Mariño; A Dominguez-Gil
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

5.  Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function.

Authors:  M Ohkawa; S Hirano; S Tokunaga; I Motoi; R Shoda; A Ikeda; T Sugata; M Sawaki; M Shimamura; A Okasho; K Kuroda
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

6.  Pharmacokinetics of single-dose cefmetazole following intramuscular administration of cefmetazole sodium to healthy male volunteers.

Authors:  H Ko; E Novak; G R Peters; W M Bothwell; J D Hosley; S K Closson; W J Adams
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

7.  Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.

Authors:  H Ko; K S Cathcart; D L Griffith; G R Peters; W J Adams
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

8.  Pharmacokinetics of intravenous cefmetazole with emphasis on comparison between predicted theoretical levels in tissue and actual skin window fluid levels.

Authors:  J S Tan; S J Salstrom; S A Signs; H E Hoffman; T M File
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.